Debbie-Ann N Nathan
Overview
Explore the profile of Debbie-Ann N Nathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
2857
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kochenderfer J, Dudley M, Kassim S, Somerville R, Carpenter R, Stetler-Stevenson M, et al.
J Clin Oncol
. 2014 Aug;
33(6):540-9.
PMID: 25154820
Purpose: T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients...
2.
Kochenderfer J, Dudley M, Feldman S, Wilson W, Spaner D, Maric I, et al.
Blood
. 2011 Dec;
119(12):2709-20.
PMID: 22160384
We conducted a clinical trial to assess adoptive transfer of T cells genetically modified to express an anti-CD19 chimeric Ag receptor (CAR). Our clinical protocol consisted of chemotherapy followed by...
3.
Parkhurst M, Yang J, Langan R, Dudley M, Nathan D, Feldman S, et al.
Mol Ther
. 2010 Dec;
19(3):620-6.
PMID: 21157437
Autologous T lymphocytes genetically engineered to express a murine T cell receptor (TCR) against human carcinoembryonic antigen (CEA) were administered to three patients with metastatic colorectal cancer refractory to standard...
4.
Kochenderfer J, Wilson W, Janik J, Dudley M, Stetler-Stevenson M, Feldman S, et al.
Blood
. 2010 Jul;
116(20):4099-102.
PMID: 20668228
Adoptive transfer of genetically modified T cells is an attractive approach for generating antitumor immune responses. We treated a patient with advanced follicular lymphoma by administering a preparative chemotherapy regimen...